Form 4: Tonix Pharmaceuticals COO Jessica Morris Reports Stock Option Grants

Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, reports the acquisition of stock options with exercise prices of $0.368 and $0.46.

Summary

• Jessica Morris, the Chief Operating Officer of Tonix Pharmaceuticals Holding Corp., filed a Form 4 on February 29, 2024, reporting changes in beneficial ownership.
• On February 27, 2024, Morris acquired two sets of stock options, each for 317,000 shares.
• One set has an exercise price of $0.368, and the other has an exercise price of $0.46.
• The options vest over three years, starting February 27, 2025, and expire on February 27, 2034.
• The options were granted under the company's Amended and Restated 2020 Stock Incentive Plan.
• Following the transaction, Morris directly owns 317,000 derivative securities for each option.

Sentiment

Score: 6

Explanation: The document is a routine filing related to stock option grants, which is generally neutral. It indicates alignment of management with shareholder interests, but doesn't provide strong positive or negative signals.

Positives

• The granting of stock options to the COO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• Companies like Pfizer, Johnson & Johnson, and Merck also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally determined based on the executive's role, performance, and industry benchmarks.

Stakeholder Impact

• The stock option grants could potentially benefit shareholders if the COO's performance leads to an increase in the company's stock price.

Key Dates